Physician profile
Crystal Bryan
NPI 1427887496
$769.57
in general payments reported to CMS, 2019-2025
13 companies · $586 in 2025
The $586 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $183 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $202.29 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $81.53 | 2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $75.82 | 2024-2025 | |
| Amgen INC. | $72.13 | 2025 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $67.60 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $52.85 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $51.75 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.63 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.68 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $33.76 | 2025 | Trelegy Ellipta |
| Lundbeck LLC | $15.20 | 2025 | Rexulti |
| Pfizer INC. | $14.55 | 2025 | |
| Lilly USA, LLC | $13.78 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.